Critical evaluation of regulatory T cells in autoimmunity

Are the most potent regulatory specificities being ignored?

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The identification of CD4+ CD25+ Foxp3+ regulatory T (Treg) cells as natural regulators of immunity in the periphery and tissues has stimulated tremendous interest in developing therapeutic strategies for autoimmune diseases. In this review, the site of origin, antigen specificity, homing markers and cytokine profiles of Treg cells were evaluated in autoimmune colitis and type 1 diabetes, two examples in which Treg cells were effective as therapy. These studies were compared with studies of Treg cells in experimental autoimmune encephalomyelitis and multiple sclerosis, where successful therapy has not yet been achieved. Antigen-specific Treg cells appear to have more potent activity than polyclonal Treg cells and therefore hold more promise as therapeutic agents. However, Treg cells specific for the pathogenic T effector cells themselves have largely been overlooked and deserve consideration in future studies.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalImmunology
Volume125
Issue number1
DOIs
StatePublished - Sep 2008

Fingerprint

Regulatory T-Lymphocytes
Autoimmunity
Antigens
Autoimmune Experimental Encephalomyelitis
Colitis
Therapeutics
Type 1 Diabetes Mellitus
Innate Immunity
Autoimmune Diseases
Multiple Sclerosis
Cytokines

Keywords

  • Experimental autoimmune encephalomyelitis
  • Experimental colitis
  • Foxp3
  • Immune therapy
  • Multiple sclerosis
  • Regulatory T cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology

Cite this

@article{eebef3d5aab54ec8bd66c8b1fa604df1,
title = "Critical evaluation of regulatory T cells in autoimmunity: Are the most potent regulatory specificities being ignored?",
abstract = "The identification of CD4+ CD25+ Foxp3+ regulatory T (Treg) cells as natural regulators of immunity in the periphery and tissues has stimulated tremendous interest in developing therapeutic strategies for autoimmune diseases. In this review, the site of origin, antigen specificity, homing markers and cytokine profiles of Treg cells were evaluated in autoimmune colitis and type 1 diabetes, two examples in which Treg cells were effective as therapy. These studies were compared with studies of Treg cells in experimental autoimmune encephalomyelitis and multiple sclerosis, where successful therapy has not yet been achieved. Antigen-specific Treg cells appear to have more potent activity than polyclonal Treg cells and therefore hold more promise as therapeutic agents. However, Treg cells specific for the pathogenic T effector cells themselves have largely been overlooked and deserve consideration in future studies.",
keywords = "Experimental autoimmune encephalomyelitis, Experimental colitis, Foxp3, Immune therapy, Multiple sclerosis, Regulatory T cells, Type 1 diabetes",
author = "Arthur Vandenbark and Halina Offner",
year = "2008",
month = "9",
doi = "10.1111/j.1365-2567.2008.02900.x",
language = "English (US)",
volume = "125",
pages = "1--13",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Critical evaluation of regulatory T cells in autoimmunity

T2 - Are the most potent regulatory specificities being ignored?

AU - Vandenbark, Arthur

AU - Offner, Halina

PY - 2008/9

Y1 - 2008/9

N2 - The identification of CD4+ CD25+ Foxp3+ regulatory T (Treg) cells as natural regulators of immunity in the periphery and tissues has stimulated tremendous interest in developing therapeutic strategies for autoimmune diseases. In this review, the site of origin, antigen specificity, homing markers and cytokine profiles of Treg cells were evaluated in autoimmune colitis and type 1 diabetes, two examples in which Treg cells were effective as therapy. These studies were compared with studies of Treg cells in experimental autoimmune encephalomyelitis and multiple sclerosis, where successful therapy has not yet been achieved. Antigen-specific Treg cells appear to have more potent activity than polyclonal Treg cells and therefore hold more promise as therapeutic agents. However, Treg cells specific for the pathogenic T effector cells themselves have largely been overlooked and deserve consideration in future studies.

AB - The identification of CD4+ CD25+ Foxp3+ regulatory T (Treg) cells as natural regulators of immunity in the periphery and tissues has stimulated tremendous interest in developing therapeutic strategies for autoimmune diseases. In this review, the site of origin, antigen specificity, homing markers and cytokine profiles of Treg cells were evaluated in autoimmune colitis and type 1 diabetes, two examples in which Treg cells were effective as therapy. These studies were compared with studies of Treg cells in experimental autoimmune encephalomyelitis and multiple sclerosis, where successful therapy has not yet been achieved. Antigen-specific Treg cells appear to have more potent activity than polyclonal Treg cells and therefore hold more promise as therapeutic agents. However, Treg cells specific for the pathogenic T effector cells themselves have largely been overlooked and deserve consideration in future studies.

KW - Experimental autoimmune encephalomyelitis

KW - Experimental colitis

KW - Foxp3

KW - Immune therapy

KW - Multiple sclerosis

KW - Regulatory T cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=49249133433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49249133433&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2567.2008.02900.x

DO - 10.1111/j.1365-2567.2008.02900.x

M3 - Article

VL - 125

SP - 1

EP - 13

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 1

ER -